Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were up 15% during mid-day trading on Friday . The stock traded as high as C$0.23 and last traded at C$0.23. Approximately 506,476 shares were traded during trading, a decline of 3% from the average daily volume of 520,039 shares. The stock had previously closed at C$0.20.
Hemostemix Price Performance
The firm has a market cap of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20. The stock has a 50-day moving average price of C$0.09 and a 200 day moving average price of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- How to Calculate Options Profits
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- Technology Stocks Explained: Here’s What to Know About Tech
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- The Significance of Brokerage Rankings in Stock Selection
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
